Antinuclear antibody-negative systemic lupus erythematosus-how common?

Area of Science:

• Immunology
• Rheumatology
• Autoimmunity

Background:

• Antinuclear antibodies (ANA) are key biomarkers for diagnosing autoimmune diseases like systemic lupus erythematosus (SLE).
• However, a subset of patients with SLE may present with negative ANA results, complicating diagnosis.
• DNA-binding capacity (DNA-bc) is an alternative serological marker.

Purpose of the Study:

• To investigate the prevalence and diagnostic utility of high DNA-binding capacity (DNA-bc) in patients lacking antinuclear antibodies (ANA).
• To assess the potential for identifying ANA-negative systemic lupus erythematosus (SLE) cases.

Main Methods:

• Retrospective analysis of five years of laboratory data for DNA-binding antibody results.
• Identification of patients with high DNA-binding capacity (DNA-bc) but negative antinuclear antibodies (ANA).
• Review of case notes to evaluate clinical diagnoses, including adherence to American Rheumatism Association (ARA) criteria for SLE.

Main Results:

• 38 patients exhibited high DNA-binding capacity (DNA-bc) without detectable antinuclear antibodies (ANA).
• Of these, 22 patients (58%) were clinically suspected of having systemic lupus erythematosus (SLE).
• Only six patients (16%) met the preliminary ARA classification criteria for SLE, highlighting diagnostic challenges.

Conclusions:

• ANA-negative SLE appears to be more prevalent than commonly recognized.
• Measurement of DNA-binding capacity (DNA-bc) should be considered in clinical evaluations where SLE is suspected but ANA tests are negative.
• This approach may improve the diagnosis of SLE in a significant patient cohort.